CD274 and cancer: Among them, PD-1 targeting drugs (Pembrolizumab and Nivolumab) or PD-L1 (Atezolizumab, Avelumab, and Durvalumab), and CTLA-4 inhibitors (Ipilimumab) can benefit treatment of several cancer types, comprising skin melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin lymphoma (22–24).